Puma Biotechnology | PBYI - Należności Handlowe





Należności Handlowe Zmiana Data
Agios Pharmaceuticals USD 10.58M 5.55M 2025-12
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
Amgen USD 9.57B 1.08B 2025-12
Biogen USD 1.85B 234M 2025-09
BioMarin Pharmaceutical USD 908.21M 117.95M 2025-12
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Exelixis USD 286.92M 24.38M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
Glaxosmithkline GBP 10.45B 707.81M 2025-12
Incyte USD 1.02B 128.52M 2025-12
MacroGenics USD 13.37M 55.86M 2025-12
Moderna USD 184M 862M 2025-12
Novartis USD 12.29B 3.3B 2025-12
Pfizer USD 18.12B 2.02B 2025-09
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sangamo BioSciences USD 581K 110K 2024-06
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Takeda JPY 757.92B 55.68B 2025-12
TG Therapeutics USD 265.38M 33.86M 2025-09
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Vertex Pharmaceuticals USD 2.05B 106.4M 2025-12